KPTI Karyopharm Therapeutics Inc.
$1.61▼ -0.62%
Healthcare
Other
After hours
$1.60▼ -0.60%
Sep 11, 7:48 PM ET
Volume 6.73M
Avg Volume (10D) 1.08M
Key Metrics & Fundamentals
Market Cap
$36.52M
P/E Ratio
–
Div Yield
–%
52W Range
1.24 - 10.99
% vs 50 MA
-65.14%
% vs 200 MA
-77.17%
RSI-14
25.4
MACD Histogram
+0.1800
Beta (1Y vs SPY)
0.60
Free Cash Flow
-$24.93M
Gross Rev
$33.43M
Gross Profit
$32.35M
EBITDA
-$53.88M
COGS
$1.09M
Operating Exp
$54.87M
Operating Income
-$22.53M
EBIT
-$22.53M
Pretax Income
-$67.02M
Net Income
-$67.02M
EPS (Diluted)
-2.32
Price & Volume History
Loading chart…
Recent News
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
BioPharma Dive · Sep 11, 2026 9:37 AM
Selinexor Sales Forecast and Market Size Analysis to 2034 | Selinexor Market Poised for Growth as Phase III Myelofibrosis Results Open New Commercial Opportunities
GlobeNewswire · Sep 10, 2026 10:11 AM
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates
Simply Wall St. · Sep 4, 2026 8:20 AM
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Sep 1, 2026 8:05 PM
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
PR Newswire · Aug 31, 2026 11:30 AM
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock
Insider Monkey · Aug 21, 2026 9:20 PM
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 20, 2026 1:43 PM
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby · Aug 14, 2026 12:30 PM
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
GuruFocus.com · Aug 13, 2026 11:09 PM
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 13, 2026 12:50 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See KPTI's money flow as a full page
Social Sentiment
No Reddit posts found for KPTI.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.